Taher Hassen, GM for Morocco and Tunisia at Merck, gives insights into navigating market access in the complex Moroccan pharma market, outlines, the challenge of introducing biosimilars, and the enduring importance of North Africa for Merck.
Morocco is a very attractive country in terms of investment, given its stable currency, good infrastructure, industrial production capacities, and connectivity with Europe and the rest of Africa
Fadela Benjelloun, executive director of LEMM, the association of multinational pharma companies in Morocco, explains the association’s key goals of improving access to healthcare and medicines, positioning Morocco as an…
Dr Driss Chaoui, CEO of Afric-Phar, one of the leading domestic companies in Moroccan pharma, provides insight into the major developments that have taken place at the company since we…
Sofia Lahlou, country manager for women’s and children’s health specialist Versalya in the Moroccan market, discusses the company’s formation, its therapeutic priorities, and the opportunities that exist for women in…
After implementing the most successful COVID-19 inoculation campaign on the African continent, Morocco is looking to bolster its biologics and vaccine manufacturing capacity via two major agreements with Swedish CDMO…
Morocco has made admirable progress in building a national oncology network in recent years, but the country’s cancer patients still face significant challenges in terms of accessing the latest therapies.…
Taher Hassen has been in position as GM for Morocco and Tunisia at Merck for four years, overseeing year-on-year double-digit growth for the affiliate ever since. His current priorities include…
See our Cookie Privacy Policy Here